The authors of the published version of this article inadvertently omitted the table note of the Table 2 under the Appendix section. The complete Table 2 is shown in this article].

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00384-020-03572-4DOI Listing

Publication Analysis

Top Keywords

correction primary
4
primary care
4
care practitioners
4
practitioners address
4
address substance
4
substance adolescents?
4
adolescents? position
4
position paper
4
paper european
4
european academy
4

Similar Publications

Proton radiotherapy significantly reduces pneumonia in oesophageal cancer patients.

Int J Radiat Oncol Biol Phys

January 2025

Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address:

Background: Neoadjuvant chemoradiotherapy (nCRT) followed by surgical resection is the current standard of care for oesophageal cancer (EC) patients. This treatment is associated with a variety of complications, with pneumonia being the most common. We hypothesize that proton radiotherapy (PRT) can significantly reduce the incidence of pneumonia compared to photon radiotherapy (PhRT).

View Article and Find Full Text PDF

A distinct immunophenotype in children carrying the Blautia enterotype: The generation R study.

Clin Immunol

January 2025

Department of Immunology, Erasmus MC, University Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands; Department of Immunology, Central Clinical School, Monash University and Alfred Hospital, Commercial Road 89, 3004 Melbourne, Victoria, Australia. Electronic address:

Objective: Studies in mouse models and human adults have shown that the intestinal microbiota composition can affect peripheral immune cells. We here examined whether the gut microbiota compositions affect B and T-cell subsets in children.

Methods: The intestinal microbiota was characterized from stool samples of 344 10-year-old children from the Generation R Study by performing 16S rRNA sequencing.

View Article and Find Full Text PDF

Loss of Insight in Syndromes Associated with Frontotemporal Lobar Degeneration: Clinical and Imaging Features.

Am J Geriatr Psychiatry

December 2024

Department of Clinical and Experimental Sciences (DA, BB), University of Brescia, Brescia, Italy; Molecular Markers Laboratory (BB), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy. Electronic address:

Objectives: The present study aims to assess the prevalence, associated clinical symptoms, longitudinal changes, and imaging correlates of Loss of Insight (LOI), which is still unexplored in syndromes associated with Frontotemporal Lobar Degeneration (FTLD).

Design: Retrospective longitudinal cohort study, from Oct 2009 to Feb 2023.

Setting: Tertiary Frontotemporal Dementia research clinic.

View Article and Find Full Text PDF

GWAS of CRP response to statins further supports the role of APOE in Statin Response: a GIST consortium study.

Pharmacol Res

January 2025

Centre of Clinical Pharmacology & Precision Medicine, William Harvey Research Institute, Queen Mary University of London, London, UK; NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, UK. Electronic address:

Article Synopsis
  • Statins are key medications used to prevent cardiovascular disease by not only lowering lipids but also reducing inflammation, measured by C-reactive protein (CRP).
  • Two significant genetic loci linked to how individuals respond to statin treatment in terms of changes in CRP levels were identified: APOE and HNF1A, both of which are associated with various health conditions like coronary artery disease and diabetes.
  • Further analysis suggests that the APOE-E4 variant may influence the effectiveness of statins, hinting at its potential role in personalized healthcare for those with cardiovascular and related conditions.
View Article and Find Full Text PDF

Background & Aims: A common genetic variant (rs738409) encoding isoleucine to methionine at position 148 in the PNPLA3 protein is a determinant of hepatic steatosis, inflammation, fibrosis, cirrhosis, and liver-related mortality. AZD2693 is a liver-targeted antisense oligonucleotide against PNPLA3 mRNA. We evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics in single ascending dose (SAD) and multiple ascending dose (MAD) studies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!